Phage Endolysin LysP108 Showed Promising Antibacterial Potential Against Methicillin-resistant Staphylococcus aureus

Frontiers in Cellular and Infection Microbiology

Zhifeng Fu¹  Qiu Zhong²  Yingran Wang³  Yan Zhao⁴  Gang Li⁴  Shuguang Lu⁴  Jing Wang⁴  Yifei Lu⁵ 

[1] College of Pharmaceutical Sciences, Southwest University, Chongqing, China;Department of Clinical Laboratory Medicine, Daping Hospital, Army Medical University, Chongqing, China;Department of Clinical Laboratory Medicine, Southwest Hospital, Army Medical University, Chongqing, China;Department of Microbiology, College of Basic Medical Science, Army Medical University, Chongqing, China;Institute of Burn Research, Southwest Hospital, State Key Lab of Trauma, Burn and Combined Injury, Army Medical University, Chongqing, China;

关键词: phage endolysin LysP108;    antibacterial activity;    drug-resistant bacteria infection treatment;    vancomycin;    methicillin-resistant Staphylococcus aureus;   

DOI  :  10.3389/fcimb.2021.668430

来源: DOAJ

【 摘 要 】

As a potential antibacterial agent, endolysin can directly lyse Gram-positive bacteria from the outside and does not lead to drug resistance. Considering that XN108 is the first reported methicillin-resistant Staphylococcus aureus (MRSA) strain in mainland China with a vancomycin MIC that exceeds 8 µg mL-1, we conducted a systematic study on its phage-encoded endolysin LysP108. Standard plate counting method revealed that LysP108 could lyse S. aureus and Pseudomonas aeruginosa with damaged outer membrane, resulting in a significant reduction in the number of live bacteria. Scanning electron microscopy results showed that S. aureus cells could be lysed directly from the outside by LysP108. Live/dead bacteria staining results indicated that LysP108 possessed strong bactericidal ability, with an anti-bacterial rate of approximately 90%. Crystal violet staining results implied that LysP108 could also inhibit and destroy bacterial biofilms. In vivo animal experiments suggested that the area of subcutaneous abscess of mice infected with MRSA was significantly reduced after the combined injection of LysP108 and vancomycin in comparison with monotherapy. The synergistic antibacterial effects of LysP108 and vancomycin were confirmed. Therefore, the present data strongly support the idea that endolysin LysP108 exhibits promising antibacterial potential to be used as a candidate for the treatment of infections caused by MRSA.

【 授权许可】

Unknown